Kornimate/medical-research-clean huggingface dataset:
reminding patients of the important of colorectal cancer screening results in patient-initiated promoting colorectal cancer screening via colonoscopy

Conditions: Colon Cancer

Summary: colorectal cancer is the third most common cancer diagnosed and third leading cause of cancer-related deaths in the united states for both men and women. the american cancer society (acs) estimates about 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer will be diagnosed, and about 49,960 deaths will occur as a result of this devastating disease in 2008. over the last 20 years, the death rate for this cancer has been dropping as a result of screening and early detection of cancer. in 2007, acs reported that early-stage colorectal cancer had a survival rate close to 80%, and up to 9,632 deaths could be prevented each year if eligible patients received screening when necessary. however, despite the proven efficacy of colorectal cancer (crc) screening, only about 50% of eligible us patients are currently being screened. specific aims the central hypothesis of this proposal is that patient-initiated prompting of primary care physicians of the patient's interest in screening will increase referrals for crc screening. the following three areas will be investigated during this research: 1. to determine whether a communication tool provided to patients will initiate a conversation with their primary care physicians about crc screening, especially via colonoscopy. 2. to determine whether this tool will impact referral patterns for screening, especially, although not primarily, among poor and underserved populations. 3. to determine whether differences exist in regard to patient-physician communication patterns about screening among residents and faculties in the fields of internal medicine and family practice clinics. at the close of the investigators study, the investigators wish to organize quantifiable data demonstrating how patient-initiated prompting of primary care physicians for crc screening increases early detection and decreases potential mortality from colorectal cancer. this data will inform a second, larger study to pursue the questions surrounding patient-initiated prompting in


Eligibility criteria:
inclusion criteria: * all patient age older than 50, exception for african american age 45 and older

Keywords: colorectal cancer screening colon cancer screening colonoscopy
synthetic genistein (bonistein™) in patients who are undergoing surgery for prostate cancer

Conditions: Prostatic Neoplasms

Summary: the purpose of this study is to evaluate safety and mechanisms of possible chemopreventive effects of synthetic genistein (bonistein™) in patients with localized prostate cancer undergoing laparoscopic radical prostatectomy.

in norway prostate cancer is the most frequently diagnosed cancer in the male and represents the second most common cause of cancer death among men. epidemiological studies have shown an association between decreased prostate cancer risk and increased soy consumption. genistein is the dominating plasma and tissue isoflavone in soybean products, and it has been attributed several anti-cancer effects. bonistein™ is a novel product, consisting of \>99,5 % synthetic genistein aglycone. chemoprevention is the ability of certain molecules to inhibit (partially or totally) induction or progression of the disease. our study population consists of men diagnosed with localized prostate cancer who have agreed to undergo radical prostatectomy. this provides adequate amount of benign, premalignant and malignant tissue for studying the effects of potential chemopreventive agents on biomarkers of cell growth and differentiation in the prostatic tissues with immunohistochemistry. prostatic tissue cells will also be selected with lacer capture microdissection (lcm) before analysis with semi-quantitative rt-pcr.

Eligibility criteria:
inclusion criteria: * histological proven prostate cancer clinical stage t1c or t2. * are to be treated by radical prostatectomy 3 to 6 weeks after consent. * have signed the informed consent form. exclusion criteria: * have been on previous or concurrent hormonal therapy or chemotherapy. * history of previous or other hormone dependent malignancies. * concomitant thyroid disease or are currently taking thyroid hormone replacement medication. * on current high dose soy, micronutrient or herbal supplements. * on soy or vegetarian nutrition or have any other extreme dietary habits. * on oral anticoagulants. * history of liver or pancreas diseases. * history of hypersensitivity to genistein or soy containing products. * have a malabsorption condition which might interfere with absorption of the investigational product.

Keywords: prostate cancer localized prostatectomy laparoscopic prostatectomy chemoprevention genistein bonistein™
a study of caregiver connections via technology in dementia

Conditions: Caregiver Stress; Dementia; Alzheimer Disease; Lewy Body Dementia; Parkinson Disease Dementia; Frontotemporal Dementia

Summary: this research is being done to develop a unique matching process for caregivers of persons living with dementia, such as alzheimer's disease, lewy body dementia, frontotemporal degeneration, or other dementia syndromes. dementia caregivers often assume greater caregiving burden than do non-dementia caregivers, and the caregiving duration tends to be longer. many caregivers do not have the adequate support they need. peer-to-peer support has been shown to improve quality of life, more engagement with services, improve caregiver health, and reduce hospitalizations in the person they are caring for. this study will help determine whether caregivers of persons with dementia would find a technology-based caregiver matching program valuable for the purpose of emotional support.


Eligibility criteria:
inclusion criteria: * the participant must have a family member that has been diagnosed with one of the following forms of dementia: parkinson's/lewy body dementia, any frontotemporal lobar degeneration dementia, or alzheimer's dementia. * the participant must identify as a care partner or caregiver who has contact with their loved one with dementia, in person or by phone, and provides social/emotional support and full or partial assistance with daily activities at least 3 days per week. * the participant must have been caring for their loved one with dementia for at least 3 months. * all participants must have access to a computer and be able to use the internet. * all participants must be english speaking. * all participants must agree to participate in the 15-month study, which includes completing questionnaires, brief "virtual" interactions with the study coordinator quarterly, and actively interacting with the website and potential matches. * all participants must agree to follow-up contact throughout the duration of the study, which is anticipated to last 3 years. exclusion criteria: * caregiver's loved one does not have a confirmed diagnosis of dementia. * caregiver is unable to provide consent. * caregiver was or has been in that role for less than 3 months.
baseline and first trimester uterine artery doppler velocimetry to predict poor obstetric outcomes in ivf

Conditions: Infertility, Female

Summary: the researchers aim to determine how baseline (preconceptional) and first-trimester uterine artery doppler measurements affect obstetric complications in women undergoing high-quality blastocyst transfer and to determine the correlation between the two doppler measurements.

only patients with high-quality blastocyst-stage embryos will be included in the study. in frozen embryo transfer cycles prepared hormonally, basal bilateral uterine artery doppler velocimetry will be performed before treatment (preconception) in each patient. bilateral uterine artery doppler velocimetry will be performed during the basal ultrasonography (2-5 days of menstruation). the absence of any uterine artery notches, diastolic or reverse flow will also be noted. in addition, sub-endometrial (arcuate artery) blood flows will be evaluated by doppler ultrasonography. for endometrial preparation, estrogen replacement will be given for approximately 12-14 days as a routine in cases with endometrial thickness ≥7mm, progesterone treatment will be started and embryo transfer will be planned on the 6th day of the treatment. in the pregnant group, measurements will be repeated at the end of the first trimester (11-14 weeks) and uterine artery doppler velocimetry will be reevaluated. in addition, patients will be followed up until delivery and possible obstetric complications will be recorded. baseline and first-trimester uterine artery doppler ultrasonography findings will be compared with obstetric results. obstetric outcomes such as birth weight at the end of pregnancy, small-large for gestational age, presence of hypertension, and preterm delivery will be correlated with preconceptional and first-trimester uterine artery doppler parameters.

Eligibility criteria:
inclusion criteria: * exogenous hormone preparation of the endometrial lining * high embryo quality ((≥2bb) according to alpha criteria * embryo transfer at the blastocyst stage exclusion criteria: * patients whose treatments were canceled for any reason before the embryo transfer procedure * patients who underwent embryo transfer in the cleavage stage * presence of low-quality (\<2bb) blastocysts * \>15% loss of viability of the embryo during embryo thawing, * patients with congenital uterine malformations, * patients in whom doppler velocimetry cannot be performed optimally

Keywords: uterine artery doppler velocimetry baseline uterine artery doppler velocimetry first trimester uterine artery doppler velocimetry
pg versus tg for advanced pgc

Conditions: Gastric Adenocarcinoma; Gastrectomy

Summary: we conducted a retrospective study on patients with pathological stage ii-iii pgc who underwent pg or tg from 2013 to 2023. propensity score-matching was applied to adjust for tumor size and stage between the pg and tg groups at a 1:1 ratio. we evaluated the procedural safety, oncological, and functional outcomes.


Eligibility criteria:
inclusion criteria: * proximal gastric adenocarcinoma after total or proximal gastrectomy. exclusion criteria: * non-curative resections * non-adenocarcinoma histology * distally located tumors or middle/proximally located tumors for which distal margin could not be secured by pg * remnant gastric cancer * clinically t1n0 tumors smaller than 3 cm for which pg was clearly indicated
implementation of telemedicine for patient with lower extremity wounds

Conditions: Peripheral Arterial Disease; Peripheral Artery Disease; Peripheral Vascular Diseases; Diabetic Foot; Diabetic Foot Ulcer; Diabetic Foot Infection; Diabetic Peripheral Neuropathy

Summary: the objective of this study is to determine if patients with lower extremity wounds in rural communities who undergo specialty referral through telemedicine have expedited care compared to patients who are treated through standard in person referral.

this is a clustered trial where patients identified as having lower extremity ulcers with peripheral artery disease and diabetes are given the option to be seen by specialty care providers through telemedicine vs. normal standard in person referral. the study is being conducted in rural areas where there are no in person vascular surgery providers. the aim of the study is to determine if patient activation affects likelihood to use telemedicine and if use of telemedicine can expedite speciality care.

Eligibility criteria:
inclusion criteria: * patient with the diagnosis of a lower extremity ulcer that has been present for longer than 2 weeks * must be willing to complete the patient activation survey * must be willing to have the study personnel call them to check in on their status exclusion criteria: * patients that do not have a telephone
high flow nasal oxygen versus vni in acute hypercapnic cardiogenic pulmonary edema

Conditions: Acute Cardiogenic Pulmonary Edema; Hypercapnic Respiratory Failure

Summary: the purpose of this study is to determine whether high flow nasal oxygen (hfno) therapy is non inferior to non invasive ventilation (niv) in the immediate treatment of patients with acute hypercapnic cardiogenic pulmonary edema associated with respiratory failure in the emergency department.

prospective multicenter study including ed patients with a suspected diagnosis of acute hypercapnic pulmonary edema with respiratory failure who require niv according to the joint recommendations from the french society of anaesthesia and intensive care and the french society for intensive care. patients will be randomly assigned to niv or high flow nasal oxygen therapy, with stratification on center and severity of hypercania. assigned treatment will be administered during at least one session of 1hr and resumed as needed based on the patient's signs of respiratory distress and blood gas results repeat evaluation of arterial blood gases, clinical parameters and dyspnea will be performed before and after the first and second hour of treatment according to current recommendation from the french society of anesthesia and intensive care medicine (sfar).

Eligibility criteria:
inclusion criteria: * asuspected diagnosis of acute pulmonary edema presenting with any of the following criteria: * dyspnea (orthopnea or a worsening of dyspnea according to nyha criteria)-respiratory rate \>20 b/min * bilateral crepitant rales at pulmonary auscultation * pulmonary infiltrate on chest x-ray * signs of respiratory failure or any of the following clinical, laboratory or or radiology signs: * use of accessory respiratory muscles * paradoxical abdominal movement * cardiomegaly (cardiothoracic ratio \>0.5) * hypertensive crisis * pao2/fio2 \ 8l/min or pao2 \<= 63mmhg breathing room air. * hypercapnia (paco2\>45) exclusion criteria: * chronic respiratory disease or associated dyspnea from non cardiac origin, * fever (\>38,5°), sepsis or ongoing infection, * contra-indication to niv, * treatment with niv or cpap prior to inclusion, including prehospital treatment

Keywords: acute cardiogenic pulmonary respiratory failure hypercapnia high flow nasal oxygen non invasive ventilation emergency department
safety and efficacy of nmd670 in ambulatory adult patients with type 3 spinal muscular atrophy

Conditions: Spinal Muscular Atrophy

Summary: the purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of nmd670 in the treatment of ambulatory adults with spinal muscular atrophy type 3


Eligibility criteria:
inclusion criteria: 1. participants with a clinical diagnosis of type 3 sma. 2. participants who are ambulatory, defined as being able to walk at least 50 metres without walking aids at screening during the 6-minute walk test. 3. participant with genetic confirmation of diagnosis (e.g., homozygous deletion or compound heterozygous deletion and mutation of survival of motor neuron 1 gene \[smn1\]) 4. participant with 3 to 5 copies of survival of motor neuron 2 gene \[smn2\]. 5. participant has a body mass index (bmi) within the range 19-35 kg/m2 (inclusive). 6. participant is male or female. 7. contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 8. participant is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in the protocol. exclusion criteria: 1. participants with prior surgery or fixed deformity (scoliosis, contractures) which would restrict ability to perform study-related tasks. 2. participants with other significant disease that may interfere with the interpretation of study data (e.g., other neuromuscular or muscular diseases). 3. participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study 4. participants received treatment with an investigational medical product (imp) within 30 days (or 5 half-lives of the medication, whichever is longer) prior to day 1. 5. participants with history of poor compliance with relevant sma therapy.

Keywords: transmission enhancer neuromuscular junction transmission clc-1
safety and efficacy of a novel malathion formulation in the treatment of head lice

Conditions: Lice Infestations

Summary: current treatments for head lice include over-the-counter products such as permethrin and prescription products such as ovide (malathion 0.5%) lotion. in a previous phase ii study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. the current study will compare the efficacy and safety of this novel formulation of malathion with ovide and with an over-the-counter permethrin product.


Eligibility criteria:
inclusion criteria: * confirmed active head lice infestation * patient, parent or guardian must be able to apply the treatment * entire household must be screened * all infested persons must agree to participate exclusion criteria: * allergy to pediculicides, hair care products or chrysanthemums * scalp conditions other than head lice * previous head lice treatment within the past 4 weeks * female patients who are pregnant or nursing

Keywords: head lice pediculosis capitis
the reliability and validity of turkish version of ''the dyspnea-als-scale (dals-15)"

Conditions: Amyotrophic Lateral Sclerosis; Dyspnea

Summary: the dyspnea-als-scale (dals-15) is a uni-dimensional scale to measure dyspnea in patients with amyotrophic lateral sclerosis. it can be easily and rapidly applied. the aim of this study is to investigate reliability and validity of turkish version of the dals-15.


Eligibility criteria:
inclusion criteria: * age of 18 or above * dyspnea on exertion, dyspnea at rest, or orthopnea without evidence of pulmonary or cardiac causes of dyspnea exclusion criteria: * severe cognitive dysfunction
association between apical periodontitis and psoriasis vulgaris

Conditions: Apical Periodontitis

Summary: the aim of the present cross-sectional study is to assess the presence of ap and caries in psoriasis vulgaris individuals and to examine whether these medications influence these oral conditions. therefore, 154 patients diagnosed with psoriasis were included in the study and subjected to oral examination to assess for presence of periapical lesions and caries experience.

the aim of the study is to evaluate the prevalence of apical periodontitis (ap) and caries in subjects with psoriasis vulgaris. 152 patients with psoriasis vulgaris were included in the study. the severity and extent of psoriasis were assessed according to the psoriasis area severity index (pasi), the body surface area (bsa), and the physician's global assessment scale (pga). periapical status was assessed through dental examination and periapical radiographs. data regarding periapical index (pai), caries experience expressed as the decayed, missing, filled teeth index (dmft), and psoriasis medications were recorded. a predictive logistic regression model for the presence of ap and a linear regression model were then built to relate the severity and extent of ap to the type of drug therapy taken for psoriasis and to the severity and extent of the skin disease.

Eligibility criteria:
inclusion criteria: * age between 18 and 70 * ability and willingness to give written consent; * presence of at least 6 teeth. * diagnosis of psoriasis vulgaris * other systemic diseases apart from psoriasis exclusion criteria: * diagnosis of periodontitis * inability or unwillingness to give informed consent; * periodontal treatment within the previous 6 months; * ongoing immunosuppressive treatments or antibiotic therapy for other systemic diseases; * pregnant or on lactation; * additional comorbidities * non endodontic lesions in maxilla/mandible; * ap diagnosed on teeth with inadequate endodontic treatments and coronal restorations

Keywords: psoriasis vulgaris
evaluation of bariatric surgery patients before and after sleeve gastrectomy in terms of nutritional status

Conditions: Obesity; Bariatric Surgery Candidate; Healthy Eating Index

Summary: background/purpose: laparoscopic sleeve gastrectomy (lsg) has been defined as an innovative surgical method for the treatment of obesity and is progressively applied worldwide. however, data on result of sleeve gastrectomy regarding energy-protein status, nutrient deficiencies and body composition are limited. the purpose of this study is to search nutritional status, body composition and biochemical parameters following lsg. methods: obese subjects (n:55) scheduled for sleeve gastrectomy were included. macro-micronutrient intake analysis, biochemical blood parameters, and anthropometric measures were performed before and 1, 3 and 6 months after lsg.

background/purpose: laparoscopic sleeve gastrectomy (lsg) has been defined as an innovative surgical method for the treatment of obesity and is progressively applied worldwide. nutritional deficiencies are identified as the possible complications of bariatric surgery. however, data on result of sleeve gastrectomy regarding energy-protein status, nutrient deficiencies and body composition are limited. the purpose of this study is to search nutritional status, body composition and biochemical parameters following lsg. methods: obese subjects (n:55) scheduled for sleeve gastrectomy were included in this study. preoperative and postoperative (1, 3 and 6th months) protein-energy and other nutrient consumptions, eating habits, food consumption diversity were evaluated with food frequency questionnaire, 3-days food diary record, three-factor eating scale and healthy eating index. also in the pre- and postoperative period; anthropometric (weight, height, waist, hip, fat free mass) values measured and biochemical blood parameters were collected.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the research, * to have sleeve gastrectomy surgery, * to be over 18 and under 65 years old * not having a perception disorder and communication problems exclusion criteria: * ages \ 65 years old * having a pacemaker (implantation) or any prosthesis (inconvenient for segmental body analysis)